File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes

TitleCardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Authors
KeywordsAntidiabetic drug
sodium–glucose co-transporter 2 inhibitor
glucagon-like peptide 1 receptor agonist
dipeptidyl peptidase-4 inhibitor
type 2 diabetes
Issue Date2021
PublisherRadcliffe Cardiology. The Journal's web site is located at https://www.cfrjournal.com/
Citation
Cardiac Failure Review, 2021, v. 7, p. article no. e04 How to Cite?
AbstractType 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.
Persistent Identifierhttp://hdl.handle.net/10722/304691
ISSN
2023 Impact Factor: 4.2
2023 SCImago Journal Rankings: 0.975
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorLo, CWH-
dc.contributor.authorFei, Y-
dc.contributor.authorCheung, BMY-
dc.date.accessioned2021-10-05T02:33:46Z-
dc.date.available2021-10-05T02:33:46Z-
dc.date.issued2021-
dc.identifier.citationCardiac Failure Review, 2021, v. 7, p. article no. e04-
dc.identifier.issn2057-7540-
dc.identifier.urihttp://hdl.handle.net/10722/304691-
dc.description.abstractType 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.-
dc.languageeng-
dc.publisherRadcliffe Cardiology. The Journal's web site is located at https://www.cfrjournal.com/-
dc.relation.ispartofCardiac Failure Review-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAntidiabetic drug-
dc.subjectsodium–glucose co-transporter 2 inhibitor-
dc.subjectglucagon-like peptide 1 receptor agonist-
dc.subjectdipeptidyl peptidase-4 inhibitor-
dc.subjecttype 2 diabetes-
dc.titleCardiovascular Outcomes in Trials of New Antidiabetic Drug Classes-
dc.typeArticle-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.authorityCheung, BMY=rp01321-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.15420/cfr.2020.19-
dc.identifier.pmid33747548-
dc.identifier.pmcidPMC7970669-
dc.identifier.hkuros326196-
dc.identifier.volume7-
dc.identifier.spagearticle no. e04-
dc.identifier.epagearticle no. e04-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats